Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Moore

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
American Journal of Rhinology|January 1, 1997
Follow-up of University of Virginia experience with the modified Lothrop procedureC W Gross, G C Zachmann, D G Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
Phase II trial of edatrexate in patients with advanced hepatocellular carcinomaR Pazdur, D F Moore, B Bready, et al.
The Western Journal of Medicine|October 1, 1992
Isolation of Borrelia burgdorferi from ticks in southern CaliforniaH B Meyers, D F Moore, G Gellert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II studyD F Moore, F Swan, J Yau, et al.
Leukemia & Lymphoma|August 26, 1998
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)P H Wiernik, D F Moore, J M Bennett, et al.
Prostate Cancer and Prostatic Diseases|June 24, 2015
Primary radiotherapy vs conservative management for localized prostate cancer--a population-based studyG L Lu-Yao, S Kim, D F Moore, et al.
Brain : a Journal of Neurology|November 16, 2006
Neuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseM Ries, H J Kim, C K Zalewski, et al.
Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
International Journal of Radiation Oncology, Biology, Physics|April 15, 2020
5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy TrialMatthew M Poppe, Zeinab A Yehia, Christopher Baker, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinomaR Pazdur, D C Medgyesy, R J Winn, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
American Journal of Rhinology|January 1, 1997
Follow-up of University of Virginia experience with the modified Lothrop procedureC W Gross, G C Zachmann, D G Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
Phase II trial of edatrexate in patients with advanced hepatocellular carcinomaR Pazdur, D F Moore, B Bready, et al.
The Western Journal of Medicine|October 1, 1992
Isolation of Borrelia burgdorferi from ticks in southern CaliforniaH B Meyers, D F Moore, G Gellert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II studyD F Moore, F Swan, J Yau, et al.
Leukemia & Lymphoma|August 26, 1998
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)P H Wiernik, D F Moore, J M Bennett, et al.
Prostate Cancer and Prostatic Diseases|June 24, 2015
Primary radiotherapy vs conservative management for localized prostate cancer--a population-based studyG L Lu-Yao, S Kim, D F Moore, et al.
Brain : a Journal of Neurology|November 16, 2006
Neuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseM Ries, H J Kim, C K Zalewski, et al.
Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
International Journal of Radiation Oncology, Biology, Physics|April 15, 2020
5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy TrialMatthew M Poppe, Zeinab A Yehia, Christopher Baker, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinomaR Pazdur, D C Medgyesy, R J Winn, et al.
Pageof 11